Biori Biotechnology

BIORI Biotechnology specializes in the development and manufacturing of biological reagents and raw materials for life sciences, in vitro diagnostics (IVD), and biopharmaceutical applications.

Leveraging strong expertise in protein engineering and molecular biology, the company delivers reliable and high-performance solutions.

Committed to quality and innovation, BIORI supports research and industry partners with tailored solutions, OEM services, and consistent product excellence.

Browse Biori Biotechnology Products

10x Fast Transfer Buffer

SKU: BR4D421-01|Size: 500 mL

10x TBST Buffer

SKU: BR4D451-01|Size: 500 mL

10x Tris-Glycine-SDS Running Buffer

SKU: BR4C361-01|Size: 500 mL

180 kDa Prestained Protein Marker

SKU: BR4C303-01|Size: 100 Reactions

3x Novel GC Buffer (Mg2+ free)

SKU: BR1A810-01|Size: 1 mL

5x PCR Enhancer

SKU: BR1A809-01|Size: 0.5 mL

5x Rapid Blocking Buffer

SKU: BR4D441-01|Size: 100 mL

5x SDS-PAGE Protein Loading Buffer

SKU: BR4C351-01|Size: 5 mL

AciI

SKU: BR1G102-01|Size: 100 U

AcuGenixTM Brizol Reagent

SKU: BR2B101|Size: 100 mL

AcuGenixTM CUT&Tag Assay Kit for Illumina

SKU: BR3E101-50|Size: 4 T

AcuGenixTM First-Strand cDNA Synthesis Kit (for Single-Cell 3′ RNA-Seq)

SKU: BR3N801-01|Size: 8 Tests

AcuGenixTM NGS DNA Clean Beads

SKU: BR3N401-01|Size: 1 mL

AcuGenixTM NGS RNA Clean Beads

SKU: BR3N402-01|Size: 1 mL

AcuGenixTM One-Step Tn5 DNA Library Prep Kit

SKU: BR3D301-01|Size: 8 Tests

AcuGenixTM RNase Inhibitor

SKU: BR1D901-02|Size: 10000 U

AcuGenixTM Super-Fidelity Master Mix

SKU: BR3M121-01|Size: 1 mL

AcuGenixTM Super-Fidelity Master Mix (Dye Plus)

SKU: BR3M121-79|Size: 1 mL

AcuGenixTM Tn5 Transposase

SKU: BR3P201-92|Size: 200 pmol

AcuGenixTM phi29 DNA Polymerase

SKU: BR3P104-54|Size: 500 U

AmpHifi EXL Master Mix

SKU: BR3M402-03|Size: 24 Tests

AmpHifi HS DNA Polymerase -V3

SKU: BR3P103-51|Size: 100 U

AmpHifi XL Master Mix

SKU: BR3M401-03|Size: 24 Tests

BCA Protein Assay Kit

SKU: BR4C201-02|Size: 500 Tests

Bradford Protein Assay Kit

SKU: BR4C202-01|Size: 800 T

BsaI

SKU: BR1G110-01|Size: 2000 U

BspEI

SKU: BR1G106-01|Size: 1000 U

BspQI

SKU: BR1G109-01|Size: 1000 U

BsrFI

SKU: BR1G107-01|Size: 1000 U

BssHII

SKU: BR1G108-01|Size: 250 U

Cell Total Protein Extraction Kit

SKU: BR4C131-01|Size: 30 Tests

DAB Peroxidase Substrate Kit

SKU: BR4D601-01|Size: 60 mL

DATP (100 mM)

SKU: BR1A803-01|Size: 1 mL

DCTP (100 mM)

SKU: BR1A805-01|Size: 1 mL

DGTP (100 mM)

SKU: BR1A806-01|Size: 1 mL

DL15000 DNA Ladder

SKU: BR1B204-01|Size: 250 µL

DL2000 DNA Ladder

SKU: BR1B202-01|Size: 250 µL

DNTP Mix (10 mM each)

SKU: BR1A802-01|Size: 1 mL

DTTP (100 mM)

SKU: BR1A804-01|Size: 1 mL

DUTP (100 mM)

SKU: BR1A807-01|Size: 1 mL

DpnI

SKU: BR1G122-01|Size: 500 U

ECL Chemiluminescent Substrate Kit

SKU: BR4D602-01|Size: 100 mL

EcoRI

SKU: BR1G111-01|Size: 5000 U

EndoFree Plasmid Maxi Kit

SKU: BR2A102-01|Size: 10 Tests

FEN1

SKU: BR1G101-01|Size: 250 U

FastAmpli Probe qPCR Master Mix (Universal ROX)

SKU: BR1E202-01|Size: 100 Tests

FastAmpli Probe qPCR Master Mix with UNG (Universal ROX)

SKU: BR1E203-01|Size: 100 Tests

FastAmpli SYBR qPCR Master Mix (Universal ROX)

SKU: BR1E102-01|Size: 500 Tests

FastAmpli SYBR qPCR Master Mix with UNG (Universal ROX)

SKU: BR1E103-01|Size: 500 Tests

Gel Extraction & PCR Cleanup Kit

SKU: BR2A103-01|Size: 50 Tests

HandyAmp Fast PCR Master Mix (Dye Plus)

SKU: BR1A401-11|Size: 5 mL

Heat-labile UDG

SKU: BR1A808-01|Size: 100 U

HhaI

SKU: BR1G104-01|Size: 1000 U

HinP1I

SKU: BR1G103-01|Size: 1000 U

HindIII

SKU: BR1G113-01|Size: 5000 U

HpaII

SKU: BR1G105-01|Size: 1000 U

Inorganic Pyrophosphatase

SKU: BR1G401-01|Size: 10 U

MluI

SKU: BR1G121-01|Size: 500 U

MscI

SKU: BR1G117-01|Size: 125 U

NC Membrane, 0.22 μm

SKU: BR4D414-01|Size: 20 PCS

NC Membrane, 0.45 μm

SKU: BR4D413-01|Size: 20 PCS

NaeI

SKU: BR1G112-01|Size: 250 U

NcoI

SKU: BR1G118-01|Size: 500 U

NdeI

SKU: BR1G119-01|Size: 2000 U

Neoscript First-Strand cDNA Synthesis Kit-V2 (+gDNA Wiper)

SKU: BR1D201-01|Size: 100 Tests

Neoscript First-Strand cDNA Synthesis Master Mix for qPCR (+gDNA Wiper)

SKU: BR1D301-02|Size: 100 Tests

Neoscript First-Strand cDNA Synthesis Master Mix for qPCR -V2 (+gDNA Wiper)

SKU: BR1D302-01|Size: 100 Tests

Neoscript One-Step Probe RT-qPCR Master Mix (Universal ROX)

SKU: BR1F201-01|Size: 100 Tests

Neoscript One-Step RT-PCR Kit

SKU: BR3M321-03|Size: 24 Tests

Neoscript One-Step RT-qPCR Master Mix with UNG (Universal ROX)

SKU: BR1F102-01|Size: 100 Tests

Neoscript One-Step SYBR RT-qPCR Master Mix (Universal ROX)

SKU: BR1F101-01|Size: 100 Tests

Neoscript RT Probe qPCR Master Mix with UNG (Universal ROX)

SKU: BR1F202-01|Size: 100 Tests

Neoscript Reverse Transcriptase

SKU: BR1D101-01|Size: 10000 U

One-Step PAGE Gel Fast Preparation Kit (10%)

SKU: BR4C333-01|Size: 125 Gels

One-Step PAGE Gel Fast Preparation Kit (12.5%)

SKU: BR4C334-01|Size: 125 Gels

One-Step PAGE Gel Fast Preparation Kit (15%)

SKU: BR4C335-01|Size: 125 Gels

One-Step PAGE Gel Fast Preparation Kit (6%)

SKU: BR4C331-01|Size: 125 Gels

One-Step PAGE Gel Fast Preparation Kit (7.5%)

SKU: BR4C332-01|Size: 125 Gels

PVDF Membrane, 0.22 μm

SKU: BR4D412-01|Size: 20 PCS

PVDF Membrane, 0.45 μm

SKU: BR4D411-01|Size: 20 PCS

Phosphatase Inhibitor Cocktail (100x)

SKU: BR4C122-00|Size: 0.05 mL

Plasmid Miniprep Kit

SKU: BR2A101-01|Size: 50 Tests

Protease Inhibitor Cocktail, EDTA-Free (100x)

SKU: BR4C121-00|Size: 0.05 mL

Protease and Phosphatase Inhibitor Cocktail, EDTA-Free (100x)

SKU: BR4C123-00|Size: 0.05 mL

RIPA Lysis Buffer (Medium)

SKU: BR4C102-00|Size: 10 mL

RIPA Lysis Buffer (Strong)

SKU: BR4C101-00|Size: 10 mL

RIPA Lysis Buffer (Weak)

SKU: BR4C103-00|Size: 10 mL

RIPA Lysis Buffer Set (Strong, Medium, and Weak)

SKU: BR4C104|Size: 3x 50 mL

RNA Ladder 1000

SKU: BP-20-10|Size: 20 µL

RNA Ladder 12000

SKU: BP-15-50|Size: 100 µL

RNA Ladder 6000

SKU: BP-10-50|Size: 100 µL

RNase R

SKU: BR1G301-01|Size: 1000 U

Robustart Fast Taq DNA Polymerase-V2

SKU: BR1A102-01|Size: 100 U

Robustart Probe qPCR Master Mix (Universal ROX)

SKU: BR1E201-01|Size: 100 Tests

Robustart SYBR qPCR Master Mix (Universal ROX)

SKU: BR1A501-03|Size: 500 Tests

Robustart Taq DNA Polymerase

SKU: BR1A101-01|Size: 100 U

Script Max First-Strand cDNA Synthesis Kit

SKU: BR3N701-03|Size: 24 Tests

SeamLess Cloning Master Mix

SKU: BR1C101-01|Size: 20 Tests

Super Ligation Master Mix

SKU: BR1C302-01|Size: 20 Reactions

Universal DNA Purification Kit

SKU: BR2E301-01|Size: 50 Tests

Resources & Documents

Product Catalog

PDF preview will load when visible...

Molecular Diagnosis Raw Materials Solutions

PDF preview will load when visible...

NGS LIBRARY SERIES

PDF preview will load when visible...

Quality Control QC

PDF preview will load when visible...

Recent Breakthroughs

Metabolomic insights into Lyme neuroborreliosis: Exploring cerebrospinal fluid for diagnostic clues.

Kuukkanen I, Pietikäinen A, Rissanen T, Hurme S, Kortela E, Hytönen J, Karonen M.

Ticks Tick Borne Dis

PMID:42001681

Free PMC article

Lyme neuroborreliosis (LNB), a disseminated manifestation of Lyme borreliosis (LB), arises when Borrelia burgdorferi sensu lato (Bbsl) spirochetes disseminate within the host and damage the peripheral nervous system and meninges, and in rare cases, also the parenchyma of the central nervous system (CNS). While early-stage LB is diagnosed clinically, accurate diagnosis of LNB requires cerebrospinal fluid (CSF) analysis, demonstrating pleocytosis and intrathecal synthesis of Bbsl-specific antibodies. There are, however, limitations in current LNB diagnostics, such as the unspecific nature of pleocytosis and post-treatment persistence of intrathecal antibodies necessitating the search for novel biomarkers. In this study, we employed untargeted ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) to profile small metabolites (<1500 Da) in CSF samples from subjects with definite acute LNB. Comparative analyses of metabolite profiles were performed between pretreatment subject samples (n = 63) and the following groups: (A) a subset of samples collected three weeks after treatment initiation from the same individuals (n = 36), (B) Bbsl antibody-negative subjects (non-LNB, n = 61), (C) subjects with other CNS infections (n = 21). Additionally, pretreatment LNB samples were compared between individuals with radiculitis (n = 40) and those without radiculitis (n = 23) (D). Out of 4222 molecular features (MFs) detected, 131 were prioritized based on statistical significance and magnitude of change for further detailed structural characterization. Altered metabolite classes included compounds from lysophospholipids [e.g., lysophosphatidylcholine (16:0), and lysophosphatidylethanolamine (18:0)], sphingomyelins [e.g., sphingomyelin (d18:1/14:0) and sphingomyelin d16:1/16:0)], sphingoid bases (e.g., d19:0 sphinganine, and 3-ketosphingosine), fatty acid amides (e.g., palmitoleamide and oleamide), cyclic phosphatidic acids [i.e., cyclic phosphatidic acid (16:0) and cyclic phosphatidic acid (18:2)], and amino acid metabolism (i.e., DL-glutamine, 5-hydroxytryptophan and DL-kynurenine). These findings underscore the potential of CSF metabolomics as a powerful complementary tool for diagnosing LNB and differentiating it from other CNS conditions. The identified metabolic signatures offer a foundation for future biomarker development and may enhance diagnostic precision, guide treatment strategies, and deepen our understanding of LNB pathogenesis.

Isotope Dilution NanoLC-MS/MS Quantitation of Methylglyoxal DNA-Protein Cross-Links: Formation and Repair in Human Cells.

Omondi RO, Barnes EM, Gurajala KC, Fisette G, Chaudray IA, Erber L.

Anal Chem

PMID:41995195

Free PMC article

DNA-protein cross-links (DPCs) represent a prevalent form of DNA damage that forms when cellular proteins become covalently trapped to DNA strands upon exposure to various endogenous and exogenous agents. Methylglyoxal is an endogenous metabolite that reacts with guanine and adenine bases in DNA and RNA, as well as cysteine, arginine, and lysine residues in proteins, generating advanced glycation end-products (AGEs), including DPCs. These modifications have been linked to human disease, including cancer, liver disease, diabetes, and neurodegenerative disorders. Herein, we present a mass spectrometry method for quantifying MGO-induced DNA-protein cross-links (DPCs) in human cells. We prepared an isotope 15 N 2 13 C 6 -dG-MGO-Lys internal standard and developed a quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for detecting and quantifying the formation and repair of dG-MGO-Lys DPCs in cells. Genomic DNA was extracted, subjected to sequential protease and nuclease digestion, purified by offline high-performance liquid chromatography (HPLC), and analyzed by LC-MS/MS. The method's standard curve showed a strong linear relationship across a concentration range of 10-1000 fmol ( R 2 = 0.9994). The method achieved limits of detection (LOD) and quantification (LOQ) of 10 and 20 fmol, respectively. Inhibition of proteasome and SPRTN activity revealed that SPRTN functions as a predominant proteolytic enzyme in MGO DPC repair. Overall, this analytical approach can offer valuable insights into the relevance of DPCs in diseases linked to elevated MGO levels.

Label-Free High-Throughput Screening of CYP3A4 Inhibitors Using Acoustic Ejection Mass Spectrometry.

Rimmer MA, Wang J, Ranathunge TA, Shi Z, Li Y, Lee D, Chai SC, Lin W, Twarog NR, Ansari AZ, Shelat AA, Young BM, Chen T, Yang L.

Anal Chem

PMID:41997578

Free PMC article

Label-free high-throughput screening (HTS) technologies have greatly accelerated early drug discovery by allowing direct measurement of biochemical activity without the need for chemical labels. Techniques like MALDI-TOF, RapidFire, desorption electrospray ionization, and acoustic-mist ionization mass spectrometry have shown strong analytical performance. More recently, acoustic droplet ejection mass spectrometry (AEMS) has emerged as a next-generation platform capable of analyzing over a thousand data points per hour. In this study, we thoroughly evaluated an AEMS workflow using cytochrome P450 3A4 (CYP3A4) as a model enzyme. Screening a library of 9702 compounds, this work represents the first successful label-free HTS campaign for CYP3A4 inhibitors in a 384-well format using AEMS. The result using nifedipine as a substrate was comparable to the widely used P450-Glo luminescence assay but with fewer inhibitor hits identifications. To further compare and parse differences between the methods and the substrates, 819 hits were retested using AEMS with luciferin isopropyl acetal, the same substrate used in the luminescence assay. The findings confirmed that both the assay method and the substrate influence which inhibitors were detected. Overall, this study established AEMS as a robust and reliable tool for CYP3A4 inhibitor screening. It offers high analytical precision, fewer false positives, compatibility with multiple substrates, and direct detection of metabolites, providing a practical way to validate hits and improve confidence in early drug discovery efforts.

Quantification of the Active Metabolites 4-Methylaminoantipyrine and 4-Aminoantipyrine of Dipyrone From Human Plasma by LC-MS/MS.

Schmidt S, Ihmsen H, Golditz T, Schüttler J, Wehrfritz A.

Int J Anal Chem

PMID:42004449

Free PMC article

Dipyrone (metamizole) is widely used as a nonopioid analgesic in perioperative and intensive care settings; however, its administration may be associated with severe adverse effects. In this study, we describe an analytical assay for the quantification of the active metabolites 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA) in human plasma using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS). In addition, the protein-unbound fractions of both metabolites were determined by ultrafiltration. Chromatographic separation was performed on a UPLC system using gradient elution, followed by MS/MS detection with an electrospray ionization source. The limits of detection for both metabolites were 100 ng/mL. Across the investigated concentration range (100-10,000 ng/mL), the relative error (%RE) ranged from -6.3% to +3.5%. Intra-day and inter-assay variability were below 10%. Method validation was conducted in accordance with the 2018 FDA Bioanalytical Method Validation Guidance, and all evaluated parameters met the required criteria for analytical accuracy and precision. The developed assay is suitable for monitoring dipyrone metabolites and may support the prevention of potential overdosing during prolonged analgesic therapy or in intensive care settings.

Metabolomics profiling of acute myelogenous leukemia patients to identify systemic differences associated with in vitro sensitivity to SYK inhibitors.

Brattås MK, Hatfield KJ, Paulsen Rye K, Reikvam H.

Metabolomics

PMID:41995902

Free PMC article

Introduction Acute myelogenous leukemia (AML) is a heterogeneous hematological malignancy. Despite therapeutic advances, high relapse rates and poor survival persist, underscoring the need for new treatment strategies. Spleen tyrosine kinase (SYK) is crucial for leukemic cell survival and proliferation, and SYK inhibition is being explored in AML therapy. Objective This study aimed to identify whether distinct baseline serum metabolic profiles can differentiate between AML patient samples exhibiting high versus low in vitro sensitivity to SYK inhibition. Methods Leukemic cells from 49 AML patients were evaluated for their in vitro antiproliferative response to SYK-selective inhibitors (entospletinib, RO9021) and dual SYK/FLT3 inhibitors (fostamatinib, TAK-659). Serum samples from the same patients were subjected to untargeted metabolomic profiling using liquid chromatography-mass spectrometry (LC-MS). Bioinformatic analyses were applied to identify metabolic signatures associated with differential drug sensitivity. Results Hierarchical clustering identified three drug sensitivity groups, i.e. high, intermediate, low. Untargeted metabolomics identified 1204 metabolites across major pathways. Comparative analyses revealed distinct metabolic differences between patients with high versus low sensitivity to SYK inhibitors. For dual SYK/FLT3 inhibitors, lipid metabolites consistently were more discriminative for drug response, while for SYK selective inhibitors the profiles were more heterogeneous. Pathway analyses highlighted alterations in amino acid, lipid, and xenobiotic metabolism, including arginine biosynthesis and glycine/serine metabolism, as potential determinators for effect of SYK inhibition. Conclusion This study highlights potential metabolite signatures associated with in vitro SYK-targeted therapy in AML. These findings support future research to identify potential serum biomarkers, guiding personalized SYK inhibition strategies in AML.